26,622 Shares in Novartis AG (NYSE:NVS) Bought by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC bought a new stake in Novartis AG (NYSE:NVS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 26,622 shares of the company's stock, valued at approximately $2,591,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Glassy Mountain Advisors Inc. lifted its stake in Novartis by 3.6% during the fourth quarter. Glassy Mountain Advisors Inc. now owns 50,559 shares of the company's stock worth $4,920,000 after purchasing an additional 1,776 shares during the last quarter. Telos Capital Management Inc. lifted its position in shares of Novartis by 3.9% during the 4th quarter. Telos Capital Management Inc. now owns 27,686 shares of the company's stock worth $2,694,000 after buying an additional 1,039 shares during the last quarter. YANKCOM Partnership acquired a new stake in Novartis in the fourth quarter valued at about $804,000. Bleakley Financial Group LLC grew its position in Novartis by 4.4% in the fourth quarter. Bleakley Financial Group LLC now owns 53,363 shares of the company's stock valued at $5,193,000 after acquiring an additional 2,227 shares during the last quarter. Finally, Robertson Stephens Wealth Management LLC raised its stake in Novartis by 6.3% during the fourth quarter. Robertson Stephens Wealth Management LLC now owns 3,526 shares of the company's stock worth $343,000 after acquiring an additional 210 shares in the last quarter. Institutional investors own 13.12% of the company's stock.

Novartis Trading Up 0.5 %

NYSE NVS traded up $0.56 on Thursday, reaching $107.56. The company had a trading volume of 2,841,536 shares, compared to its average volume of 2,014,377. The firm has a market cap of $219.85 billion, a price-to-earnings ratio of 18.29, a P/E/G ratio of 1.70 and a beta of 0.58. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The business has a 50 day moving average of $100.53 and a two-hundred day moving average of $108.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.90.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Analysts forecast that Novartis AG will post 8.42 EPS for the current year.

Analyst Ratings Changes

NVS has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 8th. BMO Capital Markets raised their target price on shares of Novartis from $118.00 to $120.00 and gave the company a "market perform" rating in a research report on Wednesday, October 30th. UBS Group reiterated a "neutral" rating on shares of Novartis in a report on Thursday. Erste Group Bank reiterated a "hold" rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, HSBC lowered Novartis from a "hold" rating to a "reduce" rating in a research report on Wednesday, December 4th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.